Kazia Therapeutics

Kazia Therapeutics

Kazia Therapeutics was established in 2017 through a repositioning of Novogen, an Australian soy-research company, into a pure-play oncology firm under Garner's leadership. The firm's origins trace to 1994, but the modern entity emerged when management pivoted the shell's cash reserves and public listing toward in-licensed clinical-stage molecules. Re-domiciling to the United States in 2024, Kazia now reports in USD and operates under Delaware law, aligning its corporate structure with its Nasdaq listing and American investor base. The firm's strategy centers on advancing therapies from Phase I safety data to Phase II/III registration trials, then partnering or out-licensing for commercial sale. Its lead asset, paxalisib (previously GDC-0084), was licensed from Genentech and targets the PI3K/AKT/mTOR pathway for glioblastoma, the most common adult primary brain cancer. A pivotal GBM AGILE trial evaluated the drug alongside other candidates across 40+ sites globally. Secondary programs included EVT801, a VEGFR3 inhibitor sourced from Sanofi, tested in renal cell carcinoma in a Phase I study at Gustave Roussy in France. Kazia historically operated direct research collaborations with academic centers in Australia and Europe, though headcount and R&D spend contracted following 2024 restructuring efforts. Kazia lists on two exchanges — the ASX and Nasdaq (KZIA) — and funds operations primarily through equity raises rather than revenue. In January 2025, the firm announced it had received an unsolicited, indicative, non-binding proposal from an undisclosed party, triggering a formal strategic review process (per the firm, January 2025). The announcement followed the August 2024 re-domiciliation to the U.S. and a concurrent 1-for-10 ADR ratio change. As of its most recent filing, the company maintained a lean management team under CEO James Garner and reported cash runway projections designed to carry programs through near-term data readouts. Kazia's structural differentiator is its status as a dual-listed microcap biotech bridging Australian and American public markets — a rare structure that allows it to access retail capital on the ASX while trading on the Nasdaq for institutional visibility. Unlike traditional venture-backed biotech firms, Kazia acquires clinical-stage assets from large pharmaceutical partners and advances them without building commercial infrastructure, functioning more as an asset-focused clinical development vehicle than a fully integrated biopharmaceutical company.